For example, zenocutuzumab, a bispecific HER2xHER3 antibody, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of Neuregulin 1-positive (NRG1+) non-small cell lung cancer and pancreatic ductal adenocarcinoma [16]. Here, NRG1 is linked to non-small cell lung carcinoma.